Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). (Q51718949)

10 April 2018

review article

1 reference

title

Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). (English)

1 reference

10 April 2018

1 reference

1 reference

Jessie R Groothuis

1 reference

10 April 2018

Hiroshi Nishida

series ordinal

1 reference

10 April 2018

publication date

1 June 2002

1 reference

10 April 2018

published in

Pediatrics International

1 reference

10 April 2018

volume

1 reference

10 April 2018

issue

1 reference

10 April 2018

page(s)

235-241

1 reference

10 April 2018

Birth weight and hospital readmission of infants born prematurely

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Respiratory syncytial virus infection in lower respiratory tract and asthma attack in hospitalized children in North Hokkaido, Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

The role of respiratory syncytial virus in acute bronchiolitis in small children in northern Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Respiratory syncytial virus-specific immunoglobulins in preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

An outbreak of respiratory syncytial virus in a bone marrow transplant center

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01558.X

10.1046/J.1442-200X.2002.01558.X

21 January 2018

Identifiers

DOI

1 reference

10 April 2018

release_iiihhcuiizbrjc7lop7itahrtu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iiihhcuiizbrjc7lop7itahrtu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

10 April 2018